# Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

> **NCT04095936** · PHASE2,PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT04095936
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-03
- **Primary completion:** 2021-10-07
- **Final completion:** 2021-10-29
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04095936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04095936, "Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04095936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*